Developing new anti-toxins to fight Clostridioides difficile infections
Targeting Clostridioides difficile with microbiome-sparing, resistant-proof anti-toxins
This study is working on new treatments for C. diff. infections that aim to fight the harmful effects of the bacteria while keeping your healthy gut bacteria safe, so you can feel better without upsetting your digestive balance.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project ID | NIH-11049067 on NIH RePORTER |
What this research studies
This research focuses on creating innovative anti-toxins that specifically target the harmful effects of Clostridioides difficile (C. diff.) infections while preserving the beneficial gut microbiome. By understanding how C. diff. produces toxins that damage gut cells, the research aims to develop treatments that can effectively combat these infections without further disrupting the gut's natural balance. The approach involves advanced methodologies to ensure that the new therapies are resistant to the bacteria's ability to develop resistance, thereby improving treatment outcomes for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who have experienced recurrent C. diff. infections or are at high risk for such infections due to prior antibiotic use.
Not a fit: Patients who have not been diagnosed with C. diff. infections or those who are not at risk for such infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for C. diff. infections, reducing the incidence of recurrent infections and improving patient recovery.
How similar studies have performed: Other research has shown promise in developing targeted therapies for C. diff., but this specific approach to creating microbiome-sparing anti-toxins is relatively novel.
Where this research is happening
Bronx, United States
- Albert Einstein College of Medicine — Bronx, United States (Active)
Researchers
- Principal investigator: Schramm, Vern L. — Albert Einstein College of Medicine
- Study coordinator: Schramm, Vern L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.